Regulatory considerations for preclinical development of anticancer drugs

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 3, 1997, Pages 173-185

  DeGeorge, Joseph J ^a   Ahn, Chang Ho ^a   Andrews, Paul A ^a   Brower, Margaret E ^a   Giorgio, Diana W ^a   Goheer, M Anwar ^a   Lee Ham, Doo Y ^a   McGuinn, W David ^a   Schmidt, Wendelyn ^a   Sun, C Joseph ^a   Tripathi, Satish C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antineoplastic agents; Guidelines; Phase I clinical trials; Toxicity tests; Toxicology

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; PRIORITY JOURNAL;

EID: 14444267319     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050726     Document Type: Article

References (49)

1. Barbui T, Rambaldi A, Parenzan L, Zucchelli M, Perico N, Remuzzi G (1992) Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet 339: 1421
2. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835
3. Borch RF, Katz JC, Lieder PH, Pleasants ME (1980) Effect of diethyldithiocarbamate rescue on tumor response to cisplatinum in a rat model. Proc Natl Acad Sci USA 77: 5441
4. Branda RF (1981) Transport of 5-methyltetrahydrofolic acid in erythrocytes from various mammalian species. J Nutr 111: 618
5. Branham WS, Zehr DR, Chen JJ, Sheehan DM (1988) Alterations in developing rat uterine cell populations after neonatal exposure to estrogens and antiestrogens. Teratology 38: 271
6. Choudary J, Contrera JF, DeFelice A, DeGeorge JJ, Farrelly JG, Fitzgerald G, Goheer MA, Jacobs A, Jordan A, Meyers L, Osterberg R, Resnick C, Sun CJ, Temple RJ (1996) Response to Monro and Mehta proposal for use of single-dose toxicology studies to support single-dose studies of new drugs in humans. Clin Pharmacol Ther 59: 265
7. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73
8. Collins JM, Grieshaber CK, Chabner BA (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82: 1321
9. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277
10. DeVita VT Jr (1993) Principles of chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice. Lippincott, Philadelphia, p 276
11. Doroshow JH, Locker GY, Myers CE (1979) Experimental animal models of adriamycin cardiotoxicity. Cancer Treat Rep 63: 855
12. Dougherty TJ (1993) Photodynamic therapy. Photochem Photobiol 58: 895
13. Faries D (1994) Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 4: 147
14. Food and Drug Administration (1994) International Conference on Harmonization. Guideline for detection of toxicity to reproduction for medicinal products. Fed Register 59: 48746
15. Food and Drug Administration (1995) International Conference on Harmonization. Toxicokinetics: the assessment of systemic exposure in toxicity studies. Fed Register 60: 11264
16. Food and Drug Administration (1995) Content and format of investigational new drug applications (INDs) for phase I studies of drugs, including well-characterized, therapeutic, biotechnology-derived products. Center for Drug Evaluation and Research, Rockville, Md.
17. Food and Drug Administration (1996) Good laboratory practice for nonclinical laboratory studies. 21 Code Federal Regulations 58: 265
18. Food and Drug Administration (1996) International Conference on Harmonization. Final guideline on the need for long-term rodent carcinogenicity studies of pharmaceuticals. Fed Register 61: 8154
19. Food and Drug Administration (1996) International Conference on Harmonization. Guidance on specific aspects of regulatory genotoxicity tests for pharmaceuticals. Fed Register 61: 18198
20. Food and Drug Administration (1996) International Conference on Harmonization. Draft guideline on testing for carcinogenicity of pharmaceuticals. Fed Register 61: 43297
21. Food and Drug Administration (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use. Center for Biologies Evaluation and Research
22. Food and Drug Administration (1997) International Conference on Harmonization. Genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals. Fed Register 62: 16025
23. Freireich EJ, Gehan EA, Rall DP, Schmidt EH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219
24. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR, Williams E, Diasio RB, Perez EA, Karp D, Reich SD, McCarroll K, Hoff JV (1995) Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 13: 490
25. Giusti RM, Iwamoto K, Hatch EE (1995) Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med 122: 778
26. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385
27. Graham MA, Workman P (1992) The impact of pharmacokinetically guided dose escalation strategics in phase I clinical trials: critical evaluation and recommendations for future studies. Ann Oncol 3: 339
28. Gralla EJ, Fleischman RW, Luthra YK, Stadnicki SW (1979) The dosing schedule dependent toxicities of adriamycin in beagle dogs and rhesus monkeys. Toxicology 13: 263
29. Grieshaber CK, Marsoni S (1986) Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat Rep 70: 65
30. Hard GC, Iatropoulos MJ, Jordan K, Radi E, Kallenberg OP, Imondi AR, Williams GM (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53: 4534
31. Iguchi T, Hirokawa M, Takasugi N (1986) Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology 42: 1
32. Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, Mehta MU, Temeck JW, Schmidt WJ, Burke G, Greenwald P, Temple RJ (1995) Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4: 1
33. Kim S, Kim DJ, Howell SB (1987) Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes. Cancer Chemother Pharmacol 19: 307
34. Lelieveld P, Vijgh WJF van der, Velzen D van (1987) Preclinical toxicology of platinum analogues in dogs. Eur J Cancer Clin Oncol 23: 1147
35. Lowe MC, Davis RD (1984) The current toxicology protocol of the National Cancer Institute. In: Helmann K, Carter SK (eds) Fundamentals of cancer chemotherapy. McGraw-Hill, New-York, p 228
36. Mettler FP, Young DM, Ward JM (1977) Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 37: 2705
37. Montandon F, Williams GM (1994) Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch Toxicol 68: 272
38. National Cancer Institute (1993) Investigator's handbook. Bethesda, Md.
39. O'Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46: 33
40. Peck CC, Barr WH, Benet EZ, Collins J, Desjardins RE, Furst DE, Harter JCJ, Levy G, Ludden T, Rodman JH, Sanathanan L, Schentag JJ, Shah VP, Sheiner LB, Skelly JP, Stanski DR, Temple RJ, Viswanathan CT, Weissinger J, Yacobi A (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 51: 465
41. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL (1993) Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. J Natl Cancer Inst 85: 1812
42. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Maillard JA (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967
43. Stone HB (1984) Leg contracture in mice: an assay of normal tissue response. Int J Radiat Oncol Biol Phys 10: 1053
44. Taguchi O (1987) Reproductive tract lesions in male mice treated neonatally with tamoxifen. Biol Reprod 37: 113
45. Taguchi O, Nishizuka Y (1985) Reproductive tract abnormalities in female mice treated neonatally with tamoxifen. Am J Obstet Gynecol 151: 675
46. Taudy M, Syka J, Popelar J, Ulehlova L (1992) Carboplatin and cisplatin ototoxicity in guinea pigs. Audiology 31: 293
47. US Interagency Staff Group on Carcinogens (1986) Chemical carcinogens: a review of the science and its associated principles. Environ Health Perspect 67: 201
48. Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J (1992) Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 10: 1
49. Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossherg SE, Borden EC (1993) Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 53: 5176